Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2841 results about "Somatic cell" patented technology

A somatic cell (from the Greek σῶμα sôma, meaning "body") or vegetal cell is any biological cell forming the body of an organism; that is, in a multicellular organism, any cell other than a gamete, germ cell, gametocyte or undifferentiated stem cell.

Bionic nanofiber-hydrogel composite biological scaffold as well as preparation method and application thereof

The invention discloses a bionic nanofiber-hydrogel composite biological scaffold as well as a preparation method and application thereof. The bionic nanofiber-hydrogel composite biological scaffold is a composite scaffold for simulating a gray-white matter partition structure of a spinal cord tissue, and comprises bionic nanofibers and a bionic hydrogel material, wherein the bionic nanofibers are arranged in an oriented manner and simulate a white matter ordered structure around the spinal cord, and the bionic hydrogel material is combined with the bionic nanofibers and simulates gray matter in the center of the spinal cord. According to the bionic nanofiber-hydrogel composite biological scaffold, the biological activity of loaded stem cells or adult cells can be improved, the problem that a large number of transplanted exogenous cells die due to unbalanced oxidative stress generated after tissue damage can be solved, and it is guaranteed that the transplanted cells reside in a damaged area and play a role; therefore, the spinal cord microenvironment is improved, proliferation and differentiation of endogenous neural stem cells are promoted, functional recovery after spinal cord injury is finally promoted, and great potential is achieved in spinal cord injury treatment.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI

Paeonia suffruticosa PoAIL6 gene and application of encoded protein thereof

The invention discloses an application of a peony PoAIL6 gene and an encoding protein thereof, and belongs to the technical field of biology. According to the invention, the peony PoAIL6 gene is cloned from a peony cultivar 'Paeonia ostii', and bioinformatics analysis is carried out. According to the invention, the peony PoAIL6 gene is transferred into arabidopsis thaliana, and phenotypic contrast finds that the number of lateral roots of the transgenic arabidopsis thaliana is significantly increased, which indicates that the overexpression of the peony PoAIL6 gene can promote the development of the root system of the arabidopsis thaliana. Arabidopsis thaliana roots are used for inducing calluses and carrying out callus differentiation, and it is found that the overexpressed peony PoAIL6 gene inhibits formation of the calluses and promotes the calluses to be differentiated into buds at the same time, which indicates that the peony PoAIL6 gene can regulate formation of arabidopsis thaliana somatic embryos. The invention provides a certain theoretical basis for establishing a complete plant regeneration and genetic transformation system of peony.
Owner:INT CENT FOR BAMBOO & RATTAN

Engineered viral like particles (EVLPS) for the selective transduction of target cells

The present disclosure provides compositions and methods for the selective transduction and genome editing of human cells (e.g., hematopoietic stem and progenitors cells, HSPCs) using engineered viral like particles (eVLPs). Aspects of the disclosure provide eVLP compositions comprising fusion proteins comprising a targeting moiety. In some embodiments, the fusion proteins comprise a cytokine conjugated to a transmembrane protein and / or an envelope glycoprotein. In other embodiments, the fusion proteins comprise a targeting moiety domain, a stalk protein domain, a transmembrane and / or envelope glycoprotein domain. Targeted-eVLP architectures comprising various targeting domains, stalk domains, transmembrane domains, and envelope glycoproteins are also provided herein. Other aspects of the disclosure provide eVLP compositions comprising envelope glycoproteins comprising non-natural sugars and methods of conjugating said eVLPs to various targeting moieties using bio-orthogonal click chemistry. Polynucleotides, vectors, cells, and kits useful for producing the articles, and performing the methods, described herein are also provided.
Owner:THE BROAD INST INC +1

Structure and function of modular microfluidic device for in-vitro modeling of human organs

A method and system to make a modular microfluidic device in a miniaturized form for cell culture, co-culture, and organ-on-a-microfluidic device as in-vitro model of human organs within compartmentalized 3D structures is described. The modular microfluidic device enables co-culturing of heterogeneous cell assemblies that are adjacent or sequentially connected to promote enhanced cell-cell interaction. In vivo-like flow into and / or from one cell growth chamber to adjacent cell growth chamber is maintained by micro-engineered porous barriers i.e., porous walls and membranes. These porous barriers provide a tool for mimicking the paracrine exchange between cells in the human body. The system comprises of a set of microelectrodes for real-time and long-term monitoring and quantitative measurement of the impact of stimuli on the epithelial tissue permeability. The modular microfluidic system provides a platform technology for bio-fabrication of variety of miniaturized in-vitro models for mimicking the structure and function of single and multi-organ models.
Owner:ALFAISAL UNIVERSITY

Construction method of agrobacterium tumefaciens-mediated masson pine genetic transformation system

The invention discloses a construction method of an agrobacterium tumefaciens mediated masson pine genetic transformation system, and belongs to the technical field of genetic engineering. According to the construction method of the agrobacterium tumefaciens-mediated masson pine genetic transformation system, immature masson pine cones are collected, embryogenic calluses are induced and cultured, the embryogenic calluses of the masson pine in a PEM III stage are used as a material, suspension pre-culture is performed to obtain an acceptor material, and the acceptor material is subjected to genetic transformation to obtain the agrobacterium tumefaciens-mediated masson pine genetic transformation system. The method comprises the following steps: firstly, carrying out tissue culture on a transgenic somatic embryo, infecting by adopting an agrobacterium infection solution with an OD600 value of 0.2-0.6, carrying out co-culture, recovery culture and screening culture, carrying out histochemical staining by adopting GUS, carrying out molecular identification to obtain a transgenic embryogenic callus, and carrying out maturation treatment to finally obtain the transgenic somatic embryo. The masson pine genetic transformation system established by the invention is stable in transformation performance and high in transformation positive rate, and when an acceptor material is masson pine embryonic callus with the genotype of 1-3-5, the transformation positive rate is as high as 100%.
Owner:NANJING FORESTRY UNIV

Nanometer antibody targeting FAP, CAR-T cell and application of nanometer antibody and CAR-T cell

The invention discloses a nanometer antibody targeting FAP, a CAR-T cell and application of the nanometer antibody and the CAR-T cell. The invention provides nano-antibodies VHH1 and VHH2 capable of simultaneously recognizing human or mouse FAP. The nano-antibodies VHH1 and VHH2 are used as antigen binding regions to be constructed in a human or mouse CAR structure, and human or mouse FAP-CAR-T cells with a killing function can be prepared. Results of the mouse FAP-CAR-T cell or the human FAP-CAR-T cell provided by the invention show that the FAP-CAR-T cell has a good treatment effect on removal of FAP positive cells, and is a novel FAP-CAR-T cell which is expected to be applied to clinical solid tumor CAR-T therapy.
Owner:JIANGSU JICUI JUCHUANG BIOTECHNOLOGY RES INST CO LTD

Recombinant human-derived II-type collagen, nucleic acid molecule, carrier, cell, composition and application of recombinant human-derived II-type collagen, nucleic acid molecule, carrier, cell and composition

The invention discloses a recombinant human-derived II-type collagen, a nucleic acid molecule, a carrier, a cell, a composition and application thereof, and relates to the technical fields of genetic engineering and synthetic biology. The recombinant human-derived II-type collagen comprises a calcium ion binding domain and has an effect of promoting osteoblast proliferation, so that the recombinant human-derived II-type collagen has a good application prospect in preparation of medical instruments and compositions. The recombinant human II-type collagen provided by the invention can be expressed in a common expression system, and has the advantages of high expression quantity and no endotoxin hidden danger. Moreover, the recombinant human II-type collagen does not carry purification labels such as histidine labels and the like, and can be purified through a molecular sieve, so that the target protein can be directly obtained finally, and the purification labels such as the histidine labels and the like do not need to be additionally cut off. The production method of the recombinant human-derived II-type collagen is suitable for industrial large-scale production, and the prepared product does not have an animal-derived infection source, so that the biological safety is higher.
Owner:XIAN GIANT BIOGENE TECH CO LTD +1

Immunoreaction evaluation method based on tumor neoantigen activity sorting

The invention relates to the technical field of biological information, in particular to an immunoreaction evaluation method based on tumor neoantigen activity sorting. The method comprises the following steps: obtaining genome data of tumor and normal tissues through whole exon sequencing, extracting multi-dimensional features of candidate somatic mutation, and screening by combining a Gaussian mixture model and a Transform model to obtain a high-confidence mutation genome set; predicting the HLA genotype of a patient based on sequencing data, translating and mutating into a peptide fragment, predicting the binding affinity of the peptide fragment and an MHC molecule by using an XGBoost model, and calculating a new antigen activity score sequence in combination with various parameters; and finally, synthesizing a new antigen peptide fragment according to a sorting result, carrying out in-vitro co-culture to detect an IFN-gamma secretion result, and dynamically optimizing a characteristic combination coefficient through a PPO algorithm to realize intelligent iterative updating, so that the accuracy of new antigen screening and the immunoreaction prediction capability are remarkably improved.
Owner:XINYI PHARMACEUTICAL (HANGZHOU) CO LTD

Cell survival rate prediction method and system based on Monte Carlo simulation carbon ion spectrum distribution

PendingCN119517202AImprove forecast accuracyMathematical modelsCheminformatics data warehousingMixed beamCarbon Ion Radiotherapy
The invention relates to the technical field of carbon ion radiotherapy relative biological effects, and discloses a cell survival rate prediction method and system based on Monte Carlo simulation carbon ion spectrum distribution. The method comprises the following steps: collecting experimental data of isolated cells to construct a cell database; based on the energy range of carbon ion radiotherapy particles and the type of secondary particles, a monte carlo method is used to construct a monoenergetic particle DNA damage database. And then constructing a cell survival rate prediction model based on DNA damage repair, and fitting cell radiation specificity parameters of the model based on a cell database to accurately reflect the radiation sensitivity of the cells. Then on the basis of the monoenergetic particle DNA damage database, the mixed beam DNA damage characteristics are determined in a dose weighting mode, the mixed beam DNA damage characteristics are input into the model subjected to parameter fitting to predict the cell survival rate, the secondary particle biological effect is considered, and the prediction accuracy of the clinical carbon ion beam relative biological effect can be improved.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Mutant cytochrome p450 enzymes with enhanced peroxygenase activity and / or altered product selectivity

The present invention relates to mutant enzymes with enhanced properties and processes for oxidation of organic compound substrates using such enzymes. More specifically, provided herein are mutations in cytochrome P450 enzymes that enhance their peroxygenase activity and / or alter product selectivity compared to wild-type cytochrome P450 enzymes. Uses for such mutant cytochrome P450 enzymes are also provided, such as for biocatalytic oxidation of carbon-hydrogen bonds via a peroxygenase pathway, or for oxidizing a substrate which is an organic compound.
Owner:UNIVERSITY OF ADELAIDE

Catechol functionalized gelatin microspheres and application thereof in preparation of products for inhibiting formation of subcutaneous effusion and promoting tissue repair

The invention provides a catechol functionalized gelatin microsphere and application of the catechol functionalized gelatin microsphere in preparation of a product for inhibiting formation of subcutaneous effusion and promoting tissue repair, and relates to the technical field of biological materials.According to the designed and prepared catechol functionalized gelatin microsphere, catechol groups are introduced into the gelatin microsphere, and the catechol functionalized gelatin microsphere is prepared; good liquid absorption performance and biodegradability are realized. Cell experiment results show that the catechol functionalized gelatin microspheres have super multiple interfaces and can promote cell adhesion and proliferation, and the loose structure of the catechol functionalized gelatin microspheres can promote cell migration. In-vivo rabbit chest wall defect repair experiment results show that the catechol functionalized gelatin microspheres not only can inhibit formation of subcutaneous effusion, but also can collect autologous cells in situ and promote proliferation of the autologous cells and secretion of extracellular matrixes (such as collagen). The results show that the catechol functionalized gelatin microsphere material has clinical application potentials of inhibiting formation of subcutaneous effusion and promoting healing of subcutaneous wounds.
Owner:QINGDAO UNIV

Cell culture microcarrier as well as preparation method and application thereof

PendingCN119286758AFacilitate migration and growthpromote growthMicrocarriers3D cultureMetaboliteCultured cell
The invention relates to a cell culture microcarrier as well as a preparation method and application thereof. The cell culture microcarrier comprises a polymer porous microsphere with an inside-outside through pore channel structure. The cell culture micro-carrier comprises a biodegradable micro-carrier and also comprises a non-degradable micro-carrier, so that the growth of cells in the carrier is facilitated, and the mass transfer of nutrient substances and metabolites is also facilitated, thereby promoting the growth of the cells, enabling the cultured cells to keep good activity and function, and being high in proliferation efficiency; the method is suitable for three-dimensional culture of somatic cells, stem cells, tumor cells and the like.
Owner:INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES

Design and application of fully human antibody for neutralizing respiratory syncytial virus

In using a fully human antibody for neutralizing respiratory syncytial virus, germline gene back mutation and affinity enhancement are performed on respiratory syncytial virus fusion protein fully-human monoclonal antibody 4F1 by using computer aided design and site-directed mutagenesis technology. The modified antibody has a relatively low number of somatic mutation sites, has high affinity, can effectively prevent RSV infection, and can also effectively inhibit the spread of RSV infection.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Il-18 fusion proteins and methods of producing il-18

Fusion proteins are provided that consist of essential elements such as one or more proteins / polypeptides capable of transporting into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. The proteins / polypeptides capable of transporting into the ER include, but are not limited to, immune globular proteins (e.g., Fc regions, VHH antibodies, and scFv), and globular proteins (e.g., serum albumin). In some embodiments, the IL-18 may be a pro-IL-18 similar to a natural precursor cytokine, wherein IL-18 is fused to the C-terminus of a propeptide or a propeptide variant thereof. In some embodiments, the fusion protein may further comprise a cleavable peptide linker.
Owner:FUSE BIOTHERAPEUTICS INC

Bispecific cytokine fusion protein and application thereof

The invention discloses a bispecific cytokine fusion protein, which comprises an amino acid sequence of a type I cytokine and an amino acid sequence of a type II cytokine, and the amino acid sequence of the type I cytokine and the amino acid sequence of the type II cytokine are directly connected through a connecting peptide or are connected in series or in parallel through a fusion partner and the connecting peptide. Amino acid sequences of type I and type II cytokines are connected in series or in parallel to form the bispecific cytokine fusion protein, and the fusion protein can synergistically activate precursor depleted CD8 + T cells and terminal depleted CD8 + T cells, improve immunosuppression of a solid tumor complex microenvironment and release the potential of tumor immunotherapy. The invention further discloses nucleic acid, a carrier, a cell, a medicine or a medicine composition related to the bispecific cytokine fusion protein. The invention also discloses application of the bispecific cytokine fusion protein in preparation of drugs for treating cancers.
Owner:ZHEJIANG UNIV

Serum-free adipogenic differentiation method for porcine fat precursor cells

The invention discloses a serum-free adipogenic differentiation method for porcine adipose precursor cells, and relates to the technical field of mammalian animal cell differentiation.In the adipogenic differentiation process, an induced differentiation culture medium and a maintained differentiation culture medium are sequentially used, and the induced differentiation culture medium is composed of a basic culture medium and cell culture auxiliary factors; the cell culture auxiliary factor is composed of 66nmol / L insulin, 33 [mu] mol / L biotin, 17 [mu] mol / L pantothenic acid, 0.1 [mu] mol / L dexamethasone, 0.25 mmol / L IBMX, 1 [mu] mol / L rosiglitazone, 150 [mu] mol / L sodium oleate and 10 [mu] g / mL transferrin; the maintenance differential medium removes IBMX and rosiglitazone on the basis of inducing the differential medium. The serum-free adipogenic differentiation method for the porcine fat precursor cells, provided by the invention, is good in differentiation effect and high in repeatability.
Owner:CHINA MEAT RES CENT

Bone organ model and construction method and application thereof

The invention provides a bone organ model as well as a construction method and application thereof, and the method comprises the following steps: arranging a biological material with a micropore array in a cell culture plate to obtain a bone organ chip; suspending the initial stem cells in a culture medium, and promoting the cells to form a spherical structure through cell aggregation or by using a non-adhesive culture surface, so as to obtain cell spheres; and culturing the cell spheres in the bone organ chip by adopting the culture medium for constructing the bone organ model to obtain the bone organ model. The skeletal organ is successfully constructed through in-vitro self-organized 3D co-culture initial stem cells including embryonic stem cells, induced pluripotent stem cells, bone marrow mesenchymal stem cells, osteoblasts, bone cells, all levels of osteogenic precursor cells, osteogenic-like cells and MC3T3-E1 cells, and the skeletal organ can become an important tool for researching and treating bone related diseases.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)

Full-automatic milk somatic cell detection system and method based on fluorescence analysis

The invention discloses a full-automatic milk somatic cell detection system and method based on fluorescence analysis. According to the full-automatic fluorescence microscopic examination system, automatic sample introduction and automatic mixing are completed through the automatic sample introduction module, automatic focusing of dyed samples is completed through the automatic focusing module, automatic photographing processing and automatic counting are completed through the automatic photographing and counting module, and therefore full-automatic fluorescence microscopic examination is achieved. According to the method, the automatic detection level is remarkably improved, the consistency of the detection process is ensured, and manual operation errors are reduced, so that the experiment efficiency, the data accuracy and the reproducibility are improved; compared with traditional off-line detection or laboratory detection, the method and system provided by the invention have better real-time performance and accuracy, and also have higher automation degree.
Owner:ZHEJIANG UNIV

Application of regulator in improvement of maturation quality of frozen porcine oocytes

ActiveCN119351320ACulture processDead animal preservationBiotechnology researchPhysiology
The invention relates to an application of a regulator in improving the maturation quality of frozen pig oocytes, the regulator is N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyryl, and the regulator improves the maturation quality of the frozen pig oocytes by improving the mitochondrial function of the frozen pig oocytes after in-vitro maturation. The invention provides a new application of N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyramide, namely the N-(2-(2-(4-chlorphenyl) thiazole-4-yl) ethyl) butyramide is used for developing a novel oocyte vitrification freezing solution and an in-vitro maturation culture solution, and the obtained high-quality oocytes can be beneficial to embryo biotechnology researches such as in-vitro fertilization and somatic cell nuclear transplantation.
Owner:YUNNAN ANIMAL SCI & VETERINARY INST

Organ-like core-shell microspheres as well as preparation method and application thereof

The invention relates to an organ-like core-shell microsphere as well as a preparation method and application thereof. The preparation method comprises the steps that 1, raw materials are prepared, specifically, shell raw materials and inner core raw materials are prepared, the shell raw materials comprise a photoinitiator and methacrylated hyaluronic acid (HAMA), and the inner core raw materials comprise organoid precursor cell suspension and matrigel; 2) molding: extruding the dispersion phase of the shell raw material wrapping the core raw material to a continuous phase by using a micro-fluidic chip and a high-precision injection pump, cutting the dispersion phase into liquid drops by the continuous phase, and performing illumination curing on the liquid drops to form core-shell microspheres; and (3) incubating, namely culturing the core-shell microspheres in a culture medium, so that the organoid precursor cells in the inner core are developed into organoids. According to the preparation method, rapid forming and curing of the organ-like precursor cells carried by the matrigel are achieved, so that the time of the organ-like precursor cells staying in the oil phase is shortened, the cells can obtain oxygen and nutrient substances, and the cell activity is improved.
Owner:QINGYUAN ZHIXIN (SHENZHEN) BIOTECHNOLOGY CO LTD

A method for constructing a donor pig for eight-gene-edited xenotransplantation

ActiveCN119177256BHydrolasesGenetically modified cellsAnimal biotechnologyFibroblast cell line
The present invention relates to a method for constructing an eight-gene-edited xenogeneic organ transplantation donor pig, belonging to the field of animal biotechnology. In the wild-type porcine fetal fibroblast cell line, the GGTA1, β4GalNT2, and CMAH genes are knocked out by using the CRISPR / Cas9 gene editing technology, and the humanized genes of hCD39, hCD46, hCD55, hCD59, and hTBM are transfected. Combining with somatic cell cloning technology, GTKO / β4GalNT2KO / CMAHKO / hCD39 / hCD46 / hCD55 / hCD59 / hTBM eight-gene-edited cloned pigs are constructed. Further, through genotype, mRNA, protein expression identification and functional analysis, eight-gene-edited xenogeneic organ transplantation donor pigs are obtained. The present invention solves the technical problems of high production difficulty, low efficiency, and low survival rate of donor pigs for multi-gene-edited xenogeneic organ transplantation, and maximally solves the common problems of immune rejection reaction and complement dysregulation faced during xenogeneic organ transplantation, laying a foundation for more targeted development of donor pigs suitable for different tissue and organ xenotransplantation, and having important value for promoting the clinical transformation of xenogeneic organ transplantation.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

CD83-binding chimeric antigen receptors

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Base editing methods and compositions for treating triplet repeat disorders

The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the HTT or FXN genes. Complexes comprising a base editor and any of the gRNAs disclosed herein are also provided by the present disclosure. The present disclosure further provides polynucleotides, vectors, cells, compositions, and kits. Methods of treating Huntington's disease and Friedreich's ataxia are also provided herein.
Owner:THE BROAD INST INC

PDRN, gene engineering vector, cell, preparation method and application thereof

The invention belongs to the technical field of gene engineering, and particularly relates to PDRN, a gene engineering vector, a cell, a preparation method and application thereof. The polydeoxyribonucleotide (PDRN) provided by the invention comprises a nucleotide sequence as shown in SEQ ID NO. 1; 1 or a partial fragment containing a nucleotide sequence shown in SEQ ID NO. 1; 1 or a sequence having 80% or more of homology with the nucleotide sequence as shown in SEQ ID NO. 1. The PDRN provided by the invention can effectively reduce and inhibit the expression level of inflammatory factors TNF-alpha and IL-6 and increase the wound healing rate of HUVEC cells, and is concentration-dependent. The PDRN provided by the invention has a good application prospect in preparation of anti-inflammatory or healing-promoting products.
Owner:HENGYU BIOPHARMACEUTICAL (SHANDONG) CO LTD +1

Cattle FTO gene promoter mutation site and application thereof

The invention provides a cattle FTO gene promoter mutation site and application thereof, and belongs to the field of biotechnology and genetic engineering, the mutation site is located in an FTO gene promoter region on a cattle genome 18 # chromosome, and the mutation site is specifically characterized in that an A base at a transcriptional start site upstream-33 base position is mutated into a G base (chromosome coordinate: Chr: 22040490); according to the mutation, the expression level of the FTO gene is remarkably improved, and the differentiation capacity of intramuscular fat precursor cells is remarkably enhanced; the FTO gene promoter mutation site provided by the invention not only can increase the gene expression quantity, but also can promote the differentiation of intramuscular fat precursor cells, and provides a solid technical basis for the cultivation of new beef cattle varieties and the increase of intramuscular fat content.
Owner:INNER MONGOLIA UNIVERSITY

Novel method to modulate expression of an endogenous gene in a somatic cell

PCT designated stage expiredWO2025078824A1HydrolasesGenetically modified cellsIntracellularSomatic cell
The invention relates to a method of modulating the expression of an endogenous gene in a somatic cell derived from an induced pluripotent stem cell (iPSC), comprising differentiating an engineered iPSC capable of stable or inducible expression of a CRISPR-related protein into a somatic cell prior to introduction of a guide RNA (gRNA) sequence. The invention also relates to the engineered iPSC, cells obtained by the method and uses thereof.
Owner:BIO BIT LTD

Somatic cell structure variation detection method based on single molecule long read length sequence chart hybrid model

The invention discloses a somatic cell structure variation detection method based on a monomolecular long-read length sequence chart hybrid model, which comprises the following steps of: extracting a read length local sequence of a target structure variation interval and a flank region thereof, constructing a local chart genome by utilizing a partial sequence alignment chart algorithm, and encoding a multi-sequence alignment result. And then, a multi-category hybrid model is combined with an expectation maximization algorithm, and clustering analysis is performed on the comparison data, so that the somatic cell structure variation category only from the tumor sample is identified. And finally, generating a consensus sequence of a somatic cell structure variation region in the tumor sample, and taking the consensus sequence as an optimization result of a local genome. Compared with an existing short-read-length sequencing method, the method has the advantages that the problems of comparison errors, low-complexity sequences and genome heterogeneity can be effectively solved, and the detection precision of somatic cell structure variation is remarkably improved. Through the application of a single-molecule long-read-length sequencing technology, more comprehensive and accurate genome information can be provided.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Stabilization of therapeutic trans-splicing RNA molecules in human cells

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.
Owner:TACIT THERAPEUTICS INC

Method for separating and purifying serrapeptase in fermentation liquor through two-step salting-out extraction

PendingCN119662609AHydrolasesElectrophoresesSalting
The invention relates to the technical field of separation and purification, and discloses a method for extracting, separating and purifying serrapeptase in fermentation liquor through two-step salting-out. The serrapeptase in the fermentation liquor is separated and purified through a two-step salting-out extraction technology, specifically, the serrapeptase in the fermentation liquor is concentrated in a lower phase through one-step salting-out extraction, bacterial cell fragments are removed, then the serrapeptase is concentrated and purified through two-step salting-out extraction, and the serrapeptase is enriched in a middle phase. The method has good separation and purification effects, after two steps of salting-out extraction, the purification multiple of the serrapeptase is 3.5 times, the recovery rate is 90.7%, the electrophoresis purity of the obtained serrapeptase is close to 100% through SDS-PAGE gray analysis, and the serrapeptase freeze-dried powder can keep the enzyme activity of 88.6% after being stored for 180 days at the temperature of-80 DEG C.
Owner:ZHEJIANG UNIV OF TECH

Palm crop protoplast gene editing method based on CRISPR / Cas9 system and application of palm crop protoplast gene editing method

The invention relates to a palm crop protoplast gene editing method based on a CRISPR / Cas9 system and application of the palm crop protoplast gene editing method, and belongs to the technical field of biology. A carrier containing PDS gene editing targets and Cas9 protein genes of palm crops is successfully delivered to protoplasts of the palm crops such as coconuts and areca nuts through protoplast transformation for the first time, and the carrier contains sgRNA sequences designed according to PAM sequences recognized by Cas9 protein. The sgRNA and Cas9 compound formed after expression in palm crop protoplast cells can be edited at a PDS gene editing target. According to the method disclosed by the invention, an editing carrier based on the CRISPR / Cas system can be delivered into the palm crop protoplast, the method is used for gene editing technology research of palm crops such as coconuts, betel nuts, oil palms, date palms and the like, and the feasibility of the method for editing the palm crop protoplast genome target gene based on the CRISPR / Cas 9 system is verified; and a rapid and effective method is provided for subsequently establishing an efficient palm crop protoplast gene editing technical system.
Owner:SANYA RES INST OF CHINESE ACAD OF TROPICAL AGRI +1